Presenting Companies
The world declared a war on opioids two decades ago. It has not worked very well. This is due to the inability of existing or emerging therapies to adequately treat severe pain. At Aether, we are developing a novel neuromodulator that suppresses the dependence signals of an opioid without interfering with analgesic function. Our Phase 2A study is designed to demonstrate POC for two potential product profiles: 1) a non-addictive pain medicine with opioid equivalent analgesia without risk of dependence; and 2) a treatment for Opioid Use Disorders.
Allogenetics is advancing an ex vivo gene therapy designed as a one-time treatment to modify donor organs, with the goal of reducing and potentially eliminating the need for lifelong immunosuppression. Our proprietary technology platform enables a calibrated knockdown of cell-surface antigen presentation (MHC class I and II) to evade graft rejection while retaining full immune competence. Building on compelling proof-of-concept in animal models, we are advancing our novel organ-agnostic approach toward human clinical trials, starting with lung and kidney grafts. Our mission is to enable longer and healthier lives for transplant patients by improving graft survival and patient quality of life.
Alveolus Bio is a team of scientists, physicians, and innovators pioneering breakthrough FDA-approved therapeutics for lung diseases. Our pipeline includes preclinical stage live biotherapeutics for Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD), and Non-Cystic Fibrosis Bronchiectasis (NCFBE). Inhaled delivery effectively targets the distal regions of the lungs, bypassing first-pass metabolism and enhancing efficacy while reducing adverse effects, differentiating our drugs from other treatments.
Avails Medical, Inc. is a pioneer in rapid, automated solutions for antibiotic susceptibility testing (AST). Founded by a team of Stanford postdoctoral researchers, Avails’ electronic biosensor technology is designed to improve affordability and speed in pathogen quantification and susceptibility testing directly from human specimens for clinical laboratories by eliminating manual, time-consuming culturing steps. Avails’ eQUANT(TM) platform enables microbiology labs to generate an automated 0.5 McFarland equivalent (eMcF) directly from positive blood cultures (PBC), removing as many as 18+ hours from the standard workflow by eliminating the need for subcultures. The eQUANT system is FDA 510(k) cleared.
Cambium Oncology is an Emory University/Winship Cancer Institute spinout developing CAMV-01, a first-in-class antagonist of the VIP/VPAC1 neuroimmune checkpoint. VIP signaling suppresses T-cell function across multiple tumor types; blocking it restores anti-tumor immunity and significantly improves responses to standard-of-care therapy. The lead indication is TP53-mutant AML, a population with a median overall survival under a year and no approved targeted option, which is where CAMV-01 is designed to extend the durability of hypomethylating-agent and FLT3-inhibitor regimens. Preclinical antitumor activity has also been demonstrated in KRAS-G12D pancreatic cancer and in prostate cancer, supporting a broader platform. The program is supported by two NCI SBIR Fast-Track awards, investments from a strategic and the founders. The company has a portfolio of 22 issued patents, with an IND targeted for Q4 2027.
Causeway Therapeutics is a clinical-stage biotech pioneering first-in-class microRNA therapies to treat tendon disease. Our lead program, TenoMiR, is a locally-delivered microRNA-29a mimic that recently completed Phase 2 in Lateral Epicondylitis, achieving promising results across all three key domains in tendinopathy – improvement in pain, function and structure. By restoring miR-29a activity at the site of injury, our approach targets the underlying collagen dysregulation, rather than simply managing symptoms. Tendinopathy presents an untapped $50BN total addressable market, of which TenoMiR targets $20BN at peak, with first-mover advantage in a space with zero approved therapies targeting tendon healing. Causeway is now raising a Series A to advance this program toward pivotal trials and expand our microRNA platform into additional tendon indications, including Rotator Cuff Tendinopathy.
Codex Labs is a science-driven plant-biotechnology company focused on the discovery and development of botanical solutions for skin and gut-microbiome-related conditions. Its technology platform investigates plant-derived bioactives and their potential to support the interconnected skin, gut, brain, and microbiome systems, with an initial focus on eczema, acne, rosacea, and psoriasis. The company’s botanical drug development strategy is complemented by clinically evaluated over-the-counter (OTC) skincare and dietary supplements, as well as an evolving telehealth model designed to support personalized care through skin-gut-brain-microbiome diagnostics. Together, these capabilities are intended to accelerate the translation of botanical science into accessible, evidence-based health solutions.
Geneius is developing an adoptive cell therapy technology that is designed to selectively unleash the patient’s immune response to cancer, and may do so in a more robust way than currently available approaches.
Geneius’ platform re-educates the patient’s own T cells to be responsive to overlooked antigens to deliver a specific and durable immune response that is less available to immune evasion. Planned applications will be for blood cancers and all solid tumors.
General Oncology is a biopharmaceutical company whose first-in-class investigational treatment GO-4 for stage IV pancreatic cancer significantly outperforms daraxonrasib in vitro and demonstrated a promising signal of efficacy in a phase 1 trial, with 2 of 4 evaluable patients at higher doses remaining free of disease at 54 and 37 months. GO-4 is given in only two cycles approximately six weeks apart, with patients receiving no further cancer therapy unless there is disease progression. Data were presented at ESMO Congress 2025. The novel redox-based mechanism of action is designed to remove drug resistance to melphalan without causing chronic toxicity to patients, allowing clinically relevant doses of melphalan—which generally have no long-term side effects—to achieve a marked potentiation in cancer cell killing while simultaneously activating other pathways of cancer cell destruction. The company was founded after its Chief Scientific and Medical Officer pioneered a new treatment approach for his sister’s pancreatic cancer; she is now more than 14 years cancer-free, having received only two cycles of therapy after surgical resection.
HedoniaUSA is a leader in the dietary management of depression. Our mantra is to ease the burden of people suffering from depression and provide them with a naturally occurring, non-pharmaceutical adjunct.
Access is the foundation. Biology is the opportunity. KIFFIK Biomedical is developing technology that enables continuous, non-invasive access to interstitial fluid (ISF), an information-rich biological fluid that has historically been difficult to access. Access to ISF expands biological visibility, enabling new insights into human biology and a deeper understanding of biology over time. KIFFIK's platform is being advanced across drug development, diagnostics, oncology and neuroscience, with broader applications in precision medicine, AI-enabled healthcare and biological research. KIFFIK is actively seeking strategic partnerships with pharmaceutical and diagnostic companies, medical technology, digital health and AI companies, sensor developers, CROs, and leading academic and research institutions to advance and scale applications enabled by non-invasive ISF access.
A pioneer in biotechnology, Merakris Therapeutics, based in Research Triangle Park, North Carolina, is a leader in researching, developing, and marketing regenerative healthcare products. We are pioneering commercially scalable biotherapeutic technologies derived from stem cells that promote homeostasis in damaged tissue. Our vision is to improve global patient care and outcomes through the pioneering and innovation of cellular regenerative biotechnologies.
Obesity care is entering a new phase—one focused not just on how much weight is lost, but on what kind of weight is lost.MS‑001 is designed precisely for this next era—delivering fat‑selective weight loss, preserving muscle health, and enhancing metabolic function to reduce cardiometabolic risk. When paired with GLP‑1 therapies, MS‑001 complements and strengthens their benefits while addressing their key limitations.
MH3D Inc. founded in 2023, headquartered in Ann Arbor, Michigan, is a medical imaging company developing next generation quantitative SPECT systems, powered by CZT detectors and advanced nuclear medicine imaging software. The company focuses on Alpha-SPECTTM platform enabling absolute quantification for theranostics across pre-clinical and future clinical applications.
Microvascular Therapeutics is a clinical stage biotechnology which pioneers in ultrasound contrast agents and theranostics. Microvascular Therapeutics (MVT) is developing a new improved ultrasound contrast agent MVT-100 via the 505(b)(2) pathway. The founders of MVT developed Definity®, the world’s #1 selling ultrasound contrast agent. Definity requires refrigerated temperature storage and has side effect of back pain. MVT-100 is a room temperature storage product and designed to eliminate the back pain. MVT has multiple theranostic products in its pipeline with multi-billion dollar market potential, the first one of which is expected to be regulated via the device pathway.
Founded in 2022 and based in Shanghai, China, Neomics Pharmaceuticals is a medical technology company that focuses on the development of tumor cellular immunotherapy. The founder of the company is Wenshan Hao. The company has a technology platform for the development of new cell therapy drugs. The company's main products include a gene therapy vector micro-loop DNA synthesis method, a tumor infiltrating T-cell in vitro expansion solution, and a novel tri-generation chimeric co-stimulatory receptor-based cell therapy drug.
Neurenati Therapeutics develops a curative combination therapy to treat Hirschsprung, a rare pediatric disease, which affects 1 newborn over 5,000 live births. Today, there is no cure. A suboptimal invasive surgical procedure is the only option that patients have, to remove the non-functional section of the colon. Neurenati’s NEU-001 combination therapy could regenerate the enteric nervous system and restore bowel movement, thus sparing the patient from the surgery.
Neuromagen Pharma is a clinical stage biopharmaceutical company pioneering a novel therapeutic approach to extending healthspan by targeting one of the fundamental hallmarks of aging: the decline of telomerase activity. Its proprietary AGS/AGP compounds transiently and controllably activate Telomerase Reverse Transcriptase (TERT), an enzyme which is a root driver of biological aging. The company's lead candidate has received FDA Orphan Drug Designation for ALS, and its compounds have shown compelling preclinical efficacy across ALS, Alzheimer's, cardiovascular, metabolic, reproductive and aesthetic medicine models. Neuromagen has completed extensive IND-enabling studies with a strong safety profile and established commercial-scale manufacturing, and is now advancing toward first-in-human trials.
Novelty Nobility is developing two bispecific antibodies centered on c-Kit, a novel therapeutic target in retinal diseases. NN4101 is a preclinical, first-in-class bispecific antibody simultaneously modulating the VEGF pathway and the c-Kit/HIF-1α axis, thereby addressing multiple key pathological drivers of disease and enhancing both treatment efficacy and durability while reducing treatment burden. NN4103 is a preclinical, first-in-class bispecific antibody designed to regulate two key pathogenic drivers of geographic atrophy—choroidal mast cells and the complement cascade.
Ordaōs is a human-enabled, machine-driven drug design company. Our miniPRO™ proteins help drug hunters deliver treatments that are safer and more effective than traditional discovery methods.
Muscle pain and spasm are the most common problem impacting the quality of life of nearly 2+ billion people world-wide. To date there is no FDA approved Topical Muscle Relaxant. Currently available drugs like, menthol, diclofenac and Lidocaine work through counter-irritant, or anti-inflammatory or anesthetic mechanisms, respectively. However, they are only treating symptoms and do not address root cause of the pain, i.e., muscle spasms. Prima has developed first-in-class, patented PI-111 to treat muscle spasms and pain in minutes to take a lead role in $5.0+ billion market without side effects like drowsiness and headache.
Repair Biotechnologies develops the proprietary Cholesterol Degrading Platform (CDP) that clears toxic excess free cholesterol inside cells, an undruggable target that existing therapies cannot meaningfully address. Treatment dramatically and rapidly improves mitochondrial function, improves overall cell function, and reduces pathology in tissues throughout the body. Cardiovascular disease accounts for ~27% of global mortality. Current treatments slow plaque growth but cannot reverse it. Repair’s lead drugs have demonstrated 20–30% plaque regression and 100% gain in treadmill endurance in just 6 weeks in preclinical models of severe atherosclerosis, improvements that continue to grow after treatment cessation. This is the only cardiovascular treatment either developed or in development that produces functional gains of this nature.
RSP Systems technology allows for integration of a wide range of biomarkers to be tracked non-invasively
Our focus is on developing the world's first non-invasive glucose tracking device targeting FDA approval in 2029
In parallel we engage with partners to integrate our platform technology across applications within health care and electronics. RSP Systems is the the only non-invasive glucose monitoring solution that has been verified in 3rd party independent clinical studies. Our ability to transfer our algorithm or AI models to new devices so that they do not have to be personalized for individual users was featured in Nature Scientific Reports.
https://www.rspsystems.com/research/publication-in-nature-scientific-reports-calibration-and-performance-of-a-raman-based-device-for-non-invasive-glucose-monitoring-in-type-2-diabetes-3
Scioto Biosciences is a clinical-stage biotechnology company developing first-in-class therapies that harness the microbiome to address serious diseases with significant unmet medical need. The company’s lead program, SB-121, is an investigational Lactobacillus reuteri-based therapeutic designed to deliver enhanced and reproducible biological activity through Scioto’s proprietary platform. SB-121 has advanced into human clinical development, with programs focused on neurological and gastrointestinal disorders, including autism spectrum disorder and necrotizing enterocolitis. Scioto is advancing SB-121 through strategic clinical, manufacturing, and technology partnerships with the goal of translating microbiome science into scalable, clinically meaningful therapies.
SciTech Development, Inc. is a clinical-stage oncology company developing innovative cancer therapies based on its patented drug delivery technology. Its lead candidate, ST-001 nanoFenretinide™ is currently being clinically evaluated in T-cell lymphoma and Small Cell Lung Cancer. The program is designed to unlock the therapeutic potential of ST-001 using its patented nanoparticle delivery technology to improve drug delivery.
Today’s cancer therapies rely on intermittent dosing, which causes unnecessary high drug peaks and subtherapeutic troughs that allow disease to escape, alongside severe toxicities. Starton Therapeutics intends to solve this issue through controlled exposure. By maintaining optimal time-on-target to eliminate toxic spikes and sub therapeutic intervals, we aim to improve both patient outcomes and quality of life.
Stingray Therapeutics is a clinical stage biotech company focused on developing next-generation immune therapies to combat cancer. Their revolutionary approach enables the full immune system to fight back against cancer, targeting innate immunity checkpoint ENPP1 to enhance immune response and reduce tumor resistance.
A clinical-stage company, Sustained Therapeutics is developing differentiated therapeutics for underserved urologic conditions. The lead program, ST-01, is a non-opioid medication for chronic pain that is being developed to provide a month or more of pain relief from a single injection. The highly successful results of its Phase 2 trial were recently highlighted in a podium presentation at the annual conference of the American Urological Association. The company’s broader pipeline extends its platform into two additional therapeutic areas, male and female sexual health and oncology. Phase 2 trials are underway in both of these products.
Targeron Therapeutics LLC is an early-stage biotech company developing multifunctional immunomodulators for the treatment of cancer and virus infection. Founded by two Rutgers professors, Dr. Raymond Birge and Dr. Sergei Kotenko, and industry veteran Dr. Rohinton Toddywala, Targeron’s technology, licensed from Rutgers and protected by global patents, combines phosphatidylserine (PS) targeting with dual interferons (type I and III). This approach delivers site-specific immune activation to boost anti-tumor activity at primary and metastatic sites and serves as a broad-spectrum antiviral. By enhancing immune cell activation and cancer cell immunogenicity, Targeron’s innovative dual-interferon strategy has the potential to pave the way for more targeted and effective therapies.